All In Biotech

Drug Trial Radar · NCT07476339

REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

A Multi-Center, Single-Arm, Open-Label, Prospective, Phase 4 Study to Investigate the Safety and Efficacy of Rapidly Restarting Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Viremic and Virologically-Suppressed Male and Female HIV-Positive Patients Aged ≥18 Years Who Are Treatment-Experienced and Returning to Care After Experiencing a Treatment Interruption of ≥12 Weeks

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jun 17, 2026

Primary completion

Jun 17, 2027

Study completion Jun 17, 2027

Sponsor

Lead sponsor
CAN Community HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Gilead Sciences; Midway Specialty Care Center; Costello Medical Inc.
First posted
Mar 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Managing HIV well requires taking antiretroviral therapy (ART) every day, but many people living with HIV experience interruptions in their treatment. These pauses in medication can happen for many reasons, such as side effects, challenges with getting to the clinic, personal circumstances, stigma, or difficulties with everyday life. When HIV treatment is stopped, the viral load can increase, which may affect a person's health and make it easier for HIV to be passed on to others. Restarting treatment quickly after an interruption is important for both personal and public health. However, it can be difficult for people who miss doses to get back on treatment right away. There are often several steps and medical appointments required before restarting, such as waiting for lab results or reviewing medical history, which can cause further delays. These additional steps can make it even harder for people to re-engage and may discourage them from returning to care. The REINITIATE study is designed for people living with HIV who have not taken any antiretroviral medications for at least the last 12 weeks. The study will offer participants a way to restart their HIV therapy quickly, by beginning treatment with B/F/TAF on the same day that they return to care. B/F/TAF is a widely used, once-daily HIV regimen, and is recommended in national treatment guidelines. Researchers want to find out if this rapid restart approach is safe and effective, and whether it helps people regain control of HIV and remain in care. The study will also examine how many participants are able to keep the virus at a low level (viral suppression), stay engaged in their HIV care, and tolerate the medication after rapidly restarting treatment. In addition, the study will include interviews with some participants, to gain a better understanding of why they stopped taking their medications and what supported their return to treatment. These insights could help healthcare teams develop better ways to support people living with HIV in the future.

Conditions

  • HIV -1 Infection
  • HIV (Human Immunodeficiency Virus)
  • HIV
  • HIV 1 Infection

Interventions

  • Bictegravir, emtricitabine, and tenofovir alafenamideDrug

    Oral, film-coated tablet containing 50 mg BIC, 200 mg FTC, and 25 mg TAF taken once daily with or without food administered for 24 or 48 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants in Cohort 1 with plasma HIV-1 RNA <50 copies/mLTime frame: Week 24
  2. Percentage of participants in Cohort 2 with plasma HIV-1 RNA ≥50 copies/mLTime frame: Week 24

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • CAN Community Health

    Clearwater, Florida · Recruiting

  • Midway Specialty Care Center

    Ft. Pierce, Florida · Recruiting

  • CAN Community Health

    Jacksonville, Florida · Recruiting

  • CAN Community Health

    Orlando, Florida · Recruiting

  • Midway Specialty Care Center

    Orlando, Florida · Recruiting

  • CAN Community Health

    Sarasota, Florida · Recruiting

  • CAN Community Health

    Tampa, Florida · Recruiting

  • Midway Specialty Care Center

    Temple Terrace, Florida · Recruiting

  • Midway Specialty Care Center

    West Palm Beach, Florida · Recruiting

  • Midway Specialty Care Center

    Wilton Manors, Florida · Recruiting

  • CAN Community Health

    Las Vegas, Nevada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.